Immunotoxin

Results: 15



#Item
1November 12, 2014 Dear Colleagues, Please find below details of a high priority clinical study just opened to patient accrual at the Northwestern Medicine Developmental Therapeutics Institute (NMDTI). A Pivotal Multicent

November 12, 2014 Dear Colleagues, Please find below details of a high priority clinical study just opened to patient accrual at the Northwestern Medicine Developmental Therapeutics Institute (NMDTI). A Pivotal Multicent

Add to Reading List

Source URL: dti.nm.org

Language: English - Date: 2014-11-12 14:34:06
2Anti-PSMA Immunotoxins Novel Targeted Therapeutics for Prostate Cancer Technology The Prostate Specific Membrane Antigen (PSMA) has been proven to be an excellent target for prostate cancer therapy. It is highly expresse

Anti-PSMA Immunotoxins Novel Targeted Therapeutics for Prostate Cancer Technology The Prostate Specific Membrane Antigen (PSMA) has been proven to be an excellent target for prostate cancer therapy. It is highly expresse

Add to Reading List

Source URL: www.campus-technologies.de

Language: English - Date: 2014-11-10 10:17:25
3Anti-PSMA Immunotoxins Novel Targeted Therapeutics for Prostate Cancer Albert-Ludwigs-Universität Freiburg Technology The Prostate Specific Membrane Antigen (PSMA) has been proven to be an excellent target for prostate

Anti-PSMA Immunotoxins Novel Targeted Therapeutics for Prostate Cancer Albert-Ludwigs-Universität Freiburg Technology The Prostate Specific Membrane Antigen (PSMA) has been proven to be an excellent target for prostate

Add to Reading List

Source URL: www.zft.uni-freiburg.de

Language: English - Date: 2011-06-06 07:53:00
4A Better Immunotoxin Through inspired engineering, proteins that enter and kill cancer cells are finding their place among cancer treatments.  (Photo: R. Baer)

A Better Immunotoxin Through inspired engineering, proteins that enter and kill cancer cells are finding their place among cancer treatments. (Photo: R. Baer)

Add to Reading List

Source URL: home.ccr.cancer.gov

Language: English - Date: 2010-07-09 15:00:30
5OBA Protocol[removed]MSKCC IRB[removed]Phase I study of In Vitro expanded allogeneic Epstein-Barr Virus specific Cytotoxic T-Lymphocytes (EBV-CTLs) genetically targeted to B cell specific antigen CD 19 positive for In

OBA Protocol[removed]MSKCC IRB[removed]Phase I study of In Vitro expanded allogeneic Epstein-Barr Virus specific Cytotoxic T-Lymphocytes (EBV-CTLs) genetically targeted to B cell specific antigen CD 19 positive for In

Add to Reading List

Source URL: osp.od.nih.gov

Language: English - Date: 2013-12-31 12:39:20
6f e a t u r e  Precision in Targeting with Anti-Mesothelin Therapies  For two decades, Raffit Hassan, M.D., Co-Chief of CCR’s Thoracic and Gastrointestinal Oncology

f e a t u r e Precision in Targeting with Anti-Mesothelin Therapies For two decades, Raffit Hassan, M.D., Co-Chief of CCR’s Thoracic and Gastrointestinal Oncology

Add to Reading List

Source URL: home.ccr.cancer.gov

Language: English - Date: 2014-07-08 18:13:38
7VB6-845 Licensing Opportunity VIVENTIA Bio Inc.  VB6-845

VB6-845 Licensing Opportunity VIVENTIA Bio Inc. VB6-845

Add to Reading List

Source URL: www.viventia.com

Language: English - Date: 2013-03-14 08:27:59
8f e a t u r e  Precision in Targeting with Anti-Mesothelin Therapies  For two decades, Raffit Hassan, M.D., Co-Chief of CCR’s Thoracic and Gastrointestinal Oncology

f e a t u r e Precision in Targeting with Anti-Mesothelin Therapies For two decades, Raffit Hassan, M.D., Co-Chief of CCR’s Thoracic and Gastrointestinal Oncology

Add to Reading List

Source URL: home.ccr.cancer.gov

Language: English - Date: 2014-06-26 13:56:08
9Fusogenics™: A novel approach to antibody affinity maturation

Fusogenics™: A novel approach to antibody affinity maturation

Add to Reading List

Source URL: www.viventia.com

Language: English - Date: 2013-03-14 08:27:25
10A preclinical profile of VB6-845: a recombinant immunotoxin for targeting ovarian cancer

A preclinical profile of VB6-845: a recombinant immunotoxin for targeting ovarian cancer

Add to Reading List

Source URL: www.viventia.com

Language: English - Date: 2013-03-14 08:26:09